NCT05998837 (GLUTREPRO) is a Phase 2, PHASE3 clinical trial of Dapagliflozin 10mg Tab in Chronic Kidney Disease, sponsored by IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy.

What drugs are being tested in NCT05998837?

Interventions in NCT05998837: Dapagliflozin 10mg Tab, Placebo.

What condition does NCT05998837 study?

NCT05998837 studies Chronic Kidney Disease, Diabetes Mellitus, Type 2, Hypertension.

Is NCT05998837 still recruiting?

NCT05998837 is currently completed. Last updated 28 March 2025.

Last reviewed 2025-03-28 · How we verify

NCT05998837: GLUTREPRO

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

GLUcose Transport and REnalPROtection in Chronic Kidney Disease

Completed Phase 2, PHASE3 Last updated 28 March 2025

What this trial tests

Phase 2, PHASE3 trial testing Dapagliflozin 10mg Tab in Chronic Kidney Disease in 34 participants. Completed in 30 September 2024.

Timeline

13 April 2021

Primary endpoint
30 September 2024

30 September 2024

Quick facts

Lead sponsor	IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
Phase	Phase 2, PHASE3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	prevention
Enrollment	34
Start date	13 April 2021
Primary completion	30 September 2024
Estimated completion	30 September 2024
Sites	1 location across Italy

Drugs / interventions tested

Dapagliflozin 10mg Tab — full drug profile →
Placebo

Conditions studied

Chronic Kidney Disease — all drugs for Chronic Kidney Disease →
Diabetes Mellitus, Type 2 — all drugs for Diabetes Mellitus, Type 2 →
Hypertension — all drugs for Hypertension →

Sponsor

IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy — full company profile →

Who can join

Adults 18 to 75, any sex, with Chronic Kidney Disease or Diabetes Mellitus, Type 2. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a single-center, double blind, randomized, parallel-arms study designed to investigate the effects of a six-month treatment with the SGLT2i dapagliflozin on markers of kidney senescence, inflammation and tubulointerstitial damage compared to placebo. These mechanisms of renal damage will be investigated in proximal tubular epithelial cells (PTECs) isolated from urine from patients with CKD with or without T2DM and in renal biopsy specimens in a subgroup of patients with diabetic kidney disease.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Proximal tubule hypertrophy and hyperfunction: a novel pathophysiological feature in disease states.
Kanbay M, Copur S, Guldan M, Ozbek L, et al · · 2024 · cited 8× · PMID 39050867 · DOI 10.1093/ckj/sfae195
Dapagliflozin Mitigates Medullary Hypoxia in CKD Patients: Analysis of Blood Oxygenation Level-Dependent Magnetic Resonance Imaging Renal Data from the Randomized Glucose Transport and Renal Protection in CKD Trial.
Russo E, Venturelli E, Di Vincenzo J, Macciò L, et al · · 2026 · cited 2× · PMID 41223002 · DOI 10.34067/kid.0000001015
Dapagliflozin Reduces Ambulatory Arterial Stiffness Index in CKD Patients with and Without Diabetes Independently of Blood Pressure Control: Results from the GLUcose Transport and Renal PROtection in Chronic Kidney Disease (GLUTREPRO) Trial.
Russo E, Cappadona F, Macciò L, Di Vincenzo J, et al · · 2026 · cited 1× · PMID 41366613 · DOI 10.1007/s40292-025-00764-3

Verify or expand the search:

Other trials of Dapagliflozin 10mg Tab

Trials testing the same drug.

NCT07056699 — SGLT2i, Pioglitazone, and Ketone Production in T1D · Phase 3 · not yet recruiting
NCT07273838 — Sodium-Glucose Cotransporter-2 Inhibitor for Patients With Acute Cardiorenal Syndrome · Phase 2 · recruiting
NCT06427226 — Evaluation of the Possible Safety and Efficacy of Dapagliflozin in the Prophylaxis of Doxorubicin-Induced Cardiotoxicity · Phase 2 · recruiting
NCT06373523 — MASLD in Primary Hypothyroidism and Efficacy of Dapaglifozin · EARLY_PHASE1 · not yet recruiting
NCT06434025 — IV Iron and SGLT2 Inhibitor on Ventricular Function and Myocardial Iron Content in Heart Failure With Iron Deficiency · Phase 3 · not yet recruiting

Other recruiting trials for Chronic Kidney Disease

Currently open trials in the same condition.

NCT07469540 — Effects of an Aerobic Exercise Program on Cardiovascular Risk in Patients With Chronic Kidney Disease or Rheumatoid Arth · NA · recruiting
NCT07169422 — Improving Kidney Care in Type 2 Diabetes: A Study of Pharmacist Prescribing Versus Usual Care · NA · recruiting
NCT07481526 — A Prospecitve Multicenter, Observational Registry Study · recruiting
NCT07450820 — OPTIMISE-CKD Study_Dapagliflozin Effectiveness in CKD · recruiting
NCT07107945 — A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease · Phase 3 · recruiting

Other IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy trials

Trials by the same sponsor.

NCT07091838 — Lung Diffusing Capacities Normality Thresholds in Pulmonary Fibrosis and Emphysema · completed
NCT05430503 — Long COVID and Post-exertional Pulmonary Diffusion · completed
NCT04610554 — Lung Diffusing Capacity for Nitric Oxide and Carbon Monoxide Early After Mild-to-severe COVID-19 · completed
NCT03601520 — Mechanisms of Pulmonary Diffusion Limitation in Systemic Sclerosis · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05998837 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
Last refreshed: 28 March 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05998837.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing